ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.
Randomized study in people · 2017
- What was studied
- 503 patients aged 60 or older after ischemic stroke; ARTEMIDA
- Main finding
- The trial reported a cognitive-scale benefit at six months. Recurrent ischemic stroke was numerically more frequent with Actovegin, without a statistically significant difference.
ADAS-cog+ change at month 6 · −6.8 Actovegin versus −4.6 placebo
Reported findings and study design
ARTEMIDA: 503 patients age ≥60, MoCA≤25, randomized within one week of stroke: Actovegin 248 versus placebo 255. Up to twenty IV infusions 2,000 mg/day, then oral 1,200 mg/day for six months; follow-up 12 months.
Population or model 503 patients aged 60 or older after ischemic stroke; ARTEMIDA
Dose, route and schedule
Actovegin: 2,000 mg/day for up to 20 intravenous infusions, followed by 1,200 mg/day orally, for six months of treatment in total. Treatment began within one week of ischemic stroke.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| ADAS-cog+ change at month 6 | −6.8 Actovegin versus −4.6 placebo | |
| Estimated treatment difference | −2.3 points; 95% CI −3.9 to −0.7 | p=0.005 |
| Recurrent ischemic stroke | More frequent with Actovegin, not statistically significant | Event counts absent from abstract |
Adjusted treatment difference is retained as −2.3 rather than replacing it with subtraction of the rounded means.
Source for these results ↗ · Reviewed 2026-10-29
Study limitations and source details
Study limitations
- Clinical importance and replication remain unresolved. The safety imbalance cannot establish causation or be dismissed as proof of safety. Disease-specific results do not establish healthy-person enhancement.
Source details
Journal publication
Indexed citation and abstract checked; full methods and risk-of-bias appraisal remain incomplete.
Sources checked
Citation
Guekht A, Skoog I, Edmundson S, Zakharov V, Korczyn AD. ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment. Stroke
Study source ↗ · DOI 10.1161/strokeaha.116.014321 · Bibliography entry · Link to this summary